Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novaferon for Hospitalized Moderate COVID-19
NCT04708158Phase 3Unknown
- Sponsor
- Genova
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of novaferon in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Genova. Primary endpoint: Time to clinical improvement at Day 28. Status: unknown.
02
Drugs
novaferon
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04708158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708158.